Summary
In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol. The Metoclopramide-induced secretion of prolactin and aldosterone was blunted in 6 patients pretreated with 200 mg ibopamine. The data are consistent with a dopaminergic effect of ibopamine due to a peripheral action, probably on D-2 receptors.
This is a preview of subscription content, log in via an institution to check access.
References
Aguilera G, Mendelsohn FAO, Catt KJ (1984) Dopaminergic regulation of aldosterone secretion. In: Martini L, Ganong WF (eds). Frontiers in neuroendocrinology. Raven Press, New York, pp 265–293
Col J, Mievis E, Reynaert M (1983) Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment. Eur J Clin Pharmacol 24: 297–300
Crosignani PG, D'Alberton A, Peracchi M, Reschini E (1976) Dopamine-induced inhibition of prolactin secretion in amenorrhoea-galactorrhoea. Lancet 2: 975
Dei Cas L, Vasini G, Manca C, Bernardini B, Visioli O (1982) Non invasive evaluation of the effects of oral ibopamine (SB 7505) on cardiac and renal function in patients with congestive heart failure. J Cardiovasc Pharmacol 4: 436–440
Del Pozo E, Brun Del Re R, Varga L, Friesen H (1972) The inhibition of prolactin secretion in man by CB 154 (2-Br-alpha-ergocryptine). J Clin Endocrinol Metab 35: 768–771
Del Pozo E, Lancranian I (1978) Clinical use of drugs modifying the release of anterior pituitary hormones. In: Ganong WF, Martini L (eds). Frontiers in neuroendocrinology. Raven Press, New York, pp 207–247
Ferrari C, Barbieri C, Caldara R, Rampini P, Paracchi A, Boghen M, Rahue W (1983) Effects of ibopamine on serum prolactin and growth horone levels in hyperprolactinemic and acromegalic subjects. Clin Pharmacol Ther 34: 74–78
Frisina N, Costa G, Buemi M (1983) Evidence for dopaminergic control of aldosterone in man. Clin Endocrinol 19: 741–745
Goldberg LI, Volkman PH, Kohli JD (1978) A comparison of the vascular dopamine receptor with other dopamine receptors. Ann Rev Pharmacol Toxicol 18: 57–79
Lombardi G, Tommasella A, Fariello C, Quattrone A, Annunziato L (1983) Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels. Eur J Clin Pharmacol 25: 131–133
Longhini C, Musacci GF, Ansani L, Toselli T, Artioli M, Bianco L, Ghirardi P (1983) Effect of ibopamine on peripheral haemodynamics. Eur J Clin Pharmacol 24: 585–589
Malarkey WD, Jacobs LS, Daughaday WH (1971) Levo-dopa suppression of prolactin in man — puerperal galactorrhea. N Engl J Med 285: 1160–1163
Melloni GF, Minoja GM, Melloni R, Piatto E, Scarazzati E, Bauer R, Ghirardi P (1981) Effectiveness of ibopaminie in the management of ascitic liver cirrhosis — A controled study versus placebo and furosemide. Br J Clin Pharmacol 12: 813–818
Peringer EP, Jenner P, Donalson IM, Marsden CD (1976) Metoclopramide and dopamine receptor blockade. Neuropharmacology 15: 463–469
Pourmand M, Rodriguez-Arnao MD, Weightman DR, Hall R, Cook DB, Lewis M, Scanlon MF (1980) Domperidone: a novel agent for investigation of anterior pituitary function and control in man. Clin Endocrinol 12: 211–215
Rolandi E, Barreca T (1984) Neuropharmacological influences on hypothalamic pituitary secretion. In: Shah WF, Donald AG (eds). Psychoneuroendocrine dysfunction. Plenum Press, New York London, pp 41–71
Stefoni S, Coli L, Mosconi G, Prandini R (1981) Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report. Br J Clin Pharmacol 1: 69–72
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rolandi, E., Marchetti, G., Franceschini, R. et al. Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. Eur J Clin Pharmacol 29, 629–630 (1986). https://doi.org/10.1007/BF00635905
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635905